WO2012139209A1 - Method and apparatus for separation of particles - Google Patents
Method and apparatus for separation of particles Download PDFInfo
- Publication number
- WO2012139209A1 WO2012139209A1 PCT/CA2012/000362 CA2012000362W WO2012139209A1 WO 2012139209 A1 WO2012139209 A1 WO 2012139209A1 CA 2012000362 W CA2012000362 W CA 2012000362W WO 2012139209 A1 WO2012139209 A1 WO 2012139209A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- obstacles
- cells
- passages
- microstructure
- particles
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 147
- 238000000926 separation method Methods 0.000 title claims abstract description 100
- 238000000034 method Methods 0.000 title claims abstract description 67
- 210000004027 cell Anatomy 0.000 claims description 226
- 239000012530 fluid Substances 0.000 claims description 127
- 230000002441 reversible effect Effects 0.000 claims description 53
- 238000009826 distribution Methods 0.000 claims description 45
- 238000003491 array Methods 0.000 claims description 36
- 230000004888 barrier function Effects 0.000 claims description 31
- 238000004891 communication Methods 0.000 claims description 15
- 210000000130 stem cell Anatomy 0.000 claims description 7
- 210000000265 leukocyte Anatomy 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 5
- 210000002308 embryonic cell Anatomy 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 238000005259 measurement Methods 0.000 abstract description 9
- 230000010355 oscillation Effects 0.000 description 53
- 239000000523 sample Substances 0.000 description 41
- 206010028980 Neoplasm Diseases 0.000 description 31
- 210000003743 erythrocyte Anatomy 0.000 description 23
- 239000010410 layer Substances 0.000 description 22
- 239000011148 porous material Substances 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 229920000642 polymer Polymers 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- 235000012431 wafers Nutrition 0.000 description 16
- 229920002120 photoresistant polymer Polymers 0.000 description 15
- 239000004205 dimethyl polysiloxane Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 13
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 230000033001 locomotion Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 9
- 230000001054 cortical effect Effects 0.000 description 9
- 229920001971 elastomer Polymers 0.000 description 9
- 239000000806 elastomer Substances 0.000 description 9
- 238000001080 multi-layer soft lithography Methods 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 230000006399 behavior Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- -1 SSC Chemical compound 0.000 description 6
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000007613 environmental effect Effects 0.000 description 6
- 239000011859 microparticle Substances 0.000 description 6
- 230000003534 oscillatory effect Effects 0.000 description 6
- 239000010703 silicon Substances 0.000 description 6
- 229910052710 silicon Inorganic materials 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 5
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008241 heterogeneous mixture Substances 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 239000004848 polyfunctional curative Substances 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000012756 surface treatment agent Substances 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000004720 dielectrophoresis Methods 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 210000005266 circulating tumour cell Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000026058 directional locomotion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 238000007387 excisional biopsy Methods 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000007386 incisional biopsy Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000010702 perfluoropolyether Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000002174 soft lithography Methods 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000004139 Choroid Plexus Neoplasms Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000008334 Dermatofibrosarcoma Diseases 0.000 description 1
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000007871 Odontogenic Tumors Diseases 0.000 description 1
- 208000012247 Oligodendroglial tumor Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- OGGXGZAMXPVRFZ-UHFFFAOYSA-M dimethylarsinate Chemical compound C[As](C)([O-])=O OGGXGZAMXPVRFZ-UHFFFAOYSA-M 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000023437 ependymal tumor Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 208000027671 high grade ependymoma Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 238000002032 lab-on-a-chip Methods 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000000516 mast-cell leukemia Diseases 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 208000010943 meningeal sarcoma Diseases 0.000 description 1
- 201000003776 meninges sarcoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000947 motile cell Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000000441 neoplastic stem cell Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 208000014500 neuronal tumor Diseases 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 239000013500 performance material Substances 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- LLHKCFNBLRBOGN-UHFFFAOYSA-N propylene glycol methyl ether acetate Chemical compound COCC(C)OC(C)=O LLHKCFNBLRBOGN-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002444 unipotent stem cell Anatomy 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- UKRDPEFKFJNXQM-UHFFFAOYSA-N vinylsilane Chemical compound [SiH3]C=C UKRDPEFKFJNXQM-UHFFFAOYSA-N 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/04—Cell isolation or sorting
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
- G01N2015/012—Red blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
- G01N2015/016—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1022—Measurement of deformation of individual particles by non-optical means
Definitions
- the present disclosure relates generally to apparatus and methods for particle separation and measurement. More particularly, the present disclosure relates to apparatus and methods that separate a heterogeneous mixture of particles, using one or more physical characteristics of the particles, and to apparatus and methods for measuring physical characteristics of particles.
- Previous micro-scale ratchet mechanisms utilize a periodic structure having local asymmetry and local excitation to modify the motion of individual particles against the viscous drag of the particle's carrier fluid (Astumian, R.D., Thermodynamics and kinetics of a Brownian motor. Science, 1997. 276(5314): p. 917-922; Julicher, F., A. Ajdari, and J. Prost, Modeling molecular motors. Reviews of Modern Physics, 1997. 69(4): p. 1269- 1281 ).
- micro-scale ratchet mechanisms exploit asymmetries of a flow on the basis of electrical potential (Bader, J.S., et al., DNA transport by a micromachined Brownian ratchet device. PNAS, 1999. 96(23): p. 13165-13169), dielectrophoresis (Gorre- Talini, L, J. P. Spatz, and P. Silberzan, Dielectrophoretic ratchets. Chaos, 1998. 8(3): p. 650-656; Rousselet, J., et al., Directional Motion of Brownian Particles Induced by a Periodic Asymmetric Potential. Nature, 1994. 370(6489): p.
- the present disclosure provides an apparatus comprising a flow channel having a first end and a second end, a fluid flow controller for causing a carrier fluid in the flow channel to alternate between flowing in a forward direction from the first end to the second end and flowing in a reverse direction from the second end to the first end, and a microstructure within the flow channel.
- the microstructure comprises one or more passages therein sized to deform particles in a carrier fluid in the flow channel as the particles pass through the microstructure, and configured such that less force is required to deform particles passing through the microstructure in the forward direction than to deform particles passing through the microstructure in the reverse direction.
- the present disclosure provides a method comprising providing a microstructure within a flow channel, the microstructure having a first side closer to a first end of the flow channel and a second side closer to a second end of the flow channel, the microstructure comprising one or more passages therein sized to deform particles in a carrier fluid in the flow channel as the particles pass through the
- microstructure configured such that less force is required to deform particles passing from the first side of the microstructure to the second side of the microstructure than to deform particles passing from the second side of the microstructure to the first side of the microstructure, and forcing the carrier fluid to alternate between flowing in a forward direction from the first end to the second end and flowing in a reverse direction from the second end to the first end.
- the present disclosure provides an apparatus for measuring particle deformability comprising an encapsulated flow channel for receiving a test particle having a size within a predetermined size range, a microfabricated constriction within the encapsulated flow channel, the constriction sized such that particles within the predetermined size range are deformed when passing through the constriction, and, a controllable pressure source in fluid communication with the encapsulated flow channel for selectively providing a controllable pressure across the constriction.
- the present disclosure provides an apparatus for measuring particle deformability, comprising a flow channel filled with carrier fluid having a first end and a second end, the flow channel configured to permit substantially unimpeded passage of particles of a first size, a constriction in the flow channel between the first end and the second end, the constriction configured such that particles of the first size are deformed by passing therethrough, a sample inlet for introducing a test particle of the first size to the first end of the flow channel, a pressure source for selectively applying a pressure gradient to the carrier fluid in the flow channel from the first end to the second end, and a controller configured to increase the pressure gradient until the test particle is forced through the constriction and output the pressure required to forced the particle through the constriction.
- Figure 1 is an apparatus for particle separation according to one embodiment of the invention.
- Figure 1A illustrates a tapered microstructure passage of an apparatus for particle separation according to another embodiment.
- Figure B illustrates a tapered microstructure passage of an apparatus for particle separation according to another embodiment.
- Figure 1C illustrates a tapered microstructure passage of an apparatus for particle separation according to another embodiment.
- Figure 2 is an apparatus for particle separation according to another embodiment of the invention.
- Figure 2A is an apparatus for particle separation according to another
- Figures 3A and 3B show a schematic deformation of a single cell through micro- scale funnel constrictions in forward and reverse directions, respectively.
- Parameters of the microstructure include the funnel pore size (W 0 ) and half-angle of the funnel taper ( ⁇ ).
- Figure 4 shows a design of a two-layer microfluidic device for measuring the pressure required to deform single cells through micro-scale funnel constrictions according to one embodiment.
- Figure 4A shows an example microfluidic device for measuring the pressure required to deform single cells through micro-scale funnel constrictions according to another embodiment.
- Figure 4B shows an example microfluidic device for measuring the pressure required to deform single cells through a single micro-scale funnel constriction according to another embodiment.
- the model curves have been fitted using a cortical tension of 750 ⁇ / ⁇ ⁇ .
- Figure 5B shows pressure asymmetry for 10°, 5°, and 0° funnel constrictions as a function of cpcell/ W 0 . Data points shown are the average pressures from 3-4
- the 'no funnel' curve is a control experiment that tracks the cell motion in an
- Figure 6B shows frequency dependence of ratchet motion with an oscillation pressure amplitude of 150 Pa.
- Figure 7A illustrates an apparatus according to another embodiment of the invention.
- Figure 7B shows the arrays of obstructions in the separation chamber of the apparatus of Figure 7A.
- Figure 7C is an enlarged view of the area indicated by box C in Figure 7B.
- Figure 8A shows distribution of a mixed sample with PBMCs (peripheral blood mononucleocytes) demonstrating a distribution peak at a funnel size of 6 ⁇ and MLCs (mouse lymphoma cells) demonstrating a distribution peak at about 9 ⁇ .
- PBMCs peripheral blood mononucleocytes
- MLCs mouse lymphoma cells
- Figure 8B is a brightfield micrograph of mixed distribution with PBMCs circled in red.
- Figure 8C is a fluorescent micrograph of mixed distribution.
- Figure 8D is a bar graph illustrating separation efficiency. Cells were separated with an applied pressure of 6.9 kPa, with a forward oscillation time of 1 second, and a reverse time of 3 seconds for 1 minute of oscillation.
- Figure 9 shows the distribution of mouse lymphoma cells over 5 separate trials.
- the applied pressure was 14 kPa, with a forward oscillation time of 1 second, and a reverse time of 3 seconds for 1 minute of oscillation.
- Figure 10 shows a distribution profile of microparticles and MLCs according to their diameter, relative to funnel size.
- the applied pressure was 6.9 kPa, with a forward oscillation time of 1 second, and a reverse time of 3 seconds for 1 minute of oscillation.
- Figures 11 A-E shows a series of graphs of the distribution of cells in a sample after 0 oscillations (Figure 11 A), 2 oscillations (Figure 11 B), 4 oscillations (Figure 11C), 6 oscillations (Figure 11D), and steady state (no further migration of cells, Figure 11 E).
- the applied pressure was 6.9kPa, with a forward oscillation time of 1 second, and a reverse time of 3 seconds.
- Figure 12 shows the distribution of cells according to the pressure applied to the flow chamber for 7 kPa, 14 kPa , 28 kPa, 41 kPa and 55 kPa.
- the oscillation time was 1 second forward and 3seconds reverse.
- Figure 13 shows the distribution of cells according to the length of the oscillation cycle for an applied pressure of 10.3 kPa.
- the forward oscillation time was 1 second, while the reverse time was as noted in the figure for 1 minute of oscillation.
- Figure 14 shows the percentage of cells exhibiting a ratcheting behavior relative to the applied pressure with a forward oscillation time of 1 second, and a reverse time of 3 seconds for 1 minute of oscillation.
- Figure 15 shows histograms comparing the cortical tensions of red blood cells treated with varying concentrations of PMS (phenazine methosulfate).
- the present disclosure provides methods, apparatus and systems for separation of particles based on physical properties of the particles, and methods, apparatus and systems for measuring physical properties of the particles.
- Certain aspects of the invention provide, in part, methods and apparatus for particle separation. More particularly, methods and apparatus for separation of particles based on physical characteristics such as size, rigidity, or size and rigidity.
- a particle may be any discrete material which can be flowed through a microscale system.
- Example particles include beads, cells and the like.
- a heterogeneous mixture of a flow of particles may comprise at least two or more types of particles or species of particles or populations of particles. The types or species or populations of particles may differ in size, rigidity, or both size and rigidity. Additionally, one or more of the particles may comprise a selectable marker, or an identifiable marker.
- Particles may be suspended in any suitable fluid, including carrier fluid, buffer, saline, water, culture medium, blood, plasma, serum, cell or tissue extract, urine or the like, or a combination thereof.
- carrier fluid including carrier fluid, buffer, saline, water, culture medium, blood, plasma, serum, cell or tissue extract, urine or the like, or a combination thereof.
- microfluidics and multi-layer soft lithography have made possible the creation of a variety of microstructures and devices that function as micrometer-scale valves and pumps. It is to be understood a microstructure is a structure comprising features where one or more dimensions measure less than about 1 mm.
- a microfluidic device refers to a micro scale device that handles volumes of liquid on the order of nanoliters or picoliters.
- microfluidic devices may, for example, be constructed on chips or the like, with microstructures formed in polymer layers on a substrate.
- some embodiments comprise microfluidic devices having a flow layer and a control layer, as described further below.
- the flow layer has a substantially constant height, which may be selected based on the sizes of the particles of interest.
- the constrictions are "tapered” or "funnel” shaped.
- a funnel constriction may be formed by a pair of triangular-shaped obstacles (see, for example, Figures 3A and 3B). Compressing cells through this constriction along the direction of the taper ("forward" direction, F) requires a smaller applied pressure than against the taper ("reverse" direction, R). Therefore, applying an unbiased pressure oscillation with amplitude above the necessary forward threshold pressure enables rectified transport along the direction of the taper.
- a ratchet refers to a device or apparatus that allows migration, or net movement, in only one direction, and prevents movement in a second or opposite direction.
- a microfluidic ratchet is an apparatus configured to permit net particle migration in one direction (a forward direction) while preventing net particle migration in a second direction (a reverse direction).
- the directional movement may be facilitated by one or more obstacles configured to permit unidirectional, or net unidirectional movement of particles, oscillating flow with greater time, velocity and/or pressure in a first direction, or a combination thereof.
- the threshold pressure required to deform a single cell through a micro-scale funnel constriction can be modeled by considering the cell as a liquid-filled sac with constant cortical tension (Hochmuth, R.M., Micropipette aspiration of living cells. Journal of Biomechanics, 2000. 33(1 ): p. 15-22).
- the end-to-end pressure required to quasi- statically form the leading and trailing surfaces in the constriction is determined by an application of the Young-Laplace law and gives equation (1 ):
- ⁇ is the pressure difference across the constriction
- T c is the cortical tension of the membrane (assumed to be isotropic and constant)
- R a and R b are the radii of the leading and the trailing surfaces respectively.
- This force asymmetry allows for controlled oscillatory flow and enables unidirectional (net-unidirectional) transport of particles through the constrictions, and as described infra, through an array.
- FIG. 1 schematically illustrates an example apparatus 100 according to one embodiment.
- Apparatus 100 comprises a flow channel 102 in fluid communication with a fluid flow controller 104.
- Fluid flow controller is operable to selectively cause a carrier fluid in flow channel 102 to alternate between flowing in a forward direction F from a first end 106 of flow channel 102 to a second end 108 of flow channel 102, and in a reverse direction R from second end 108 to first end 106 of flow channel.
- Fluid flow controller 104 may comprise, for example, one or more controllable pressure sources for urging carrier fluid to flow in either direction in channel 102.
- One or more pressure control structures and other elements for affecting the flow of fluid to channel 102 may also be provided, such as, for example pressure attenuators, extended microfluidic channels, valves, fluidic multiplexers, perfusion chambers, or the like.
- a microstructure 1 10 is positioned within the flow channel 102 between first and second ends 106 and 08.
- Microstructure 10 comprises a passage 11 sized to deform particles in the carrier fluid as the particles pass through passage 1 1 1 , and tapered such that less pressure is required to force a particle through passage 11 in the forward direction F than in the reverse direction R.
- passage 1 1 1 is sized such that the ratio of the cross-sectional area of the particle and the cross-sectional area of the passage is between about 2.2 and about 4.5.
- tapeered in connection with a passage, pore, funnel, or the like, refers to an opening through a body which is larger on one side of the body and smaller on the other side of the body.
- the expression “tapered in the forward direction” refers to an opening whose size decreases as one traverses the opening in the forward direction.
- passage 1 1 1 is formed between a pair of obstacles on either side of the flow channel 102 having opposed angled surfaces 1 12 and 1 14.
- Surfaces 1 12 and 1 14 are sometimes referred to as forming a "funnel".
- Surfaces 1 12 and 114 may be substantially flat in some embodiments.
- Surfaces 1 12 and 1 14 may be oriented at an angle of greater than 0 degrees to about 60 degrees to each other in some embodiments (e.g., the funnel has a half angle of greater than 0 degrees to about 30 degrees). In some embodiments, surfaces 1 12 and 1 14 are oriented at an angle of about 2 degrees to each other (e.g. the funnel has a half angle of about 1 degree).
- surfaces 1 12 and 1 14 are oriented at an angle of about 10 degrees to each other (e.g. the funnel has a half angle of about 5 degrees). In some embodiments, surfaces 1 12 and 1 14 are oriented at an angle of about 20 degrees to each other (e.g. the funnel has a half angle of about 0 degrees).
- FIG. 1A-C show microstructures 1 10A-1 10C according to other embodiments.
- Microstructure 1 10A of Figure 1A comprises a passage 1 1 1 A formed between a pair of obstacles on either side of the flow channel 102 having opposed stepped surfaces 1 12A and 1 14A.
- Microstructure 1 10B of Figure 1 B comprises a passage 1 1 B formed between a pair of obstacles on either side of the flow channel 102 having opposed curved surfaces 1 12B and 1 14B.
- Microstructure 1 10C of Figure 1 C comprises a pair of passages 1 1 1 C formed on either side of a single obstacle 1 13 located at approximately the centre of the flow channel 102, whereby the shape of obstacle 1 13 provides the desired tapering of passages 1 1 1 C.
- Figure 2 shows an apparatus 200 according to another embodiment.
- the flow channel comprises a separation chamber 202 having first and second ends 206 and 208 and opposed sidewalls 203.
- chamber 202 is depicted as generally rectangular in the illustrated example, this is not required in all embodiments.
- a fluid flow controller (not shown in Figure 2) distributes carrier fluid into separation chamber 202 at the first and second ends 206 and 208 thereof through one or more carrier fluid channels 205 and 207, respectively, to cause the carrier fluid to alternate between flowing in the forward F and reverse R directions.
- Filter barriers may be provided at either end of chamber 202 to prevent particles in chamber 202 from entering carrier fluid channels 205 and 207.
- a microstructure comprising an array 210 of obstacles 212 is disposed within separation chamber 202. Passages 21 1 are formed between adjacent obstacles 212.
- the opening width (or pore size, W 0 , see Figures 3A and 3B) of passages 211 is selected to be smaller than the size of particles to be separated, such that the particles are deformed as they are travel through passages 211 .
- the length 2 3 of passages 211 is determined by the length of obstacles 212.
- a sample inlet 220 is positioned to introduce a sample of particles suspended in carrier fluid into chamber 202 between first end 206 and array 210.
- First and second sample outlets 231 and 232 are positioned on either side of array 210 for removing separated particles from chamber 202.
- Inlet 220 and outlets 231 , 232 may be opened and closed by means of suitable valves.
- inlet 220 is opened to allow a sample of particles into chamber 202, then inlet is closed and the carrier fluid is oscillated within chamber 202 by alternately providing pressurized carrier fluid from carrier fluid channels 205 and 207.
- the applied pressures are selected based on expected threshold pressures to force the particles through passages 211.
- the forward pressure may be selected to be greater than the threshold pressure to force a particle through one of the passages 211 in the forward direction
- the reverse pressure may be selected to be less than the threshold pressure to force a particle through one of the passages in the reverse direction such that the particle is prevented from transiting through a passage in the reverse direction.
- Oscillation of the carrier fluid causes deformable particles to accumulate between the array 2 0 and the second end 208, while more rigid particles accumulate between the array 210 and the first end 206.
- the deformable particles which have passed through array 210 are removed through outlet 232 and the more rigid particles which have not passed through array 2 0 are removed through outlet 231.
- additional inlets may be provided for introducing additional carrier fluid for flushing particles out outlets 231 and 232 after separation.
- Figure 2A shows an apparatus 200A according to another embodiment.
- Apparatus 200A has a number of elements in common with apparatus 200 of Figure 2, which are identified with corresponding reference numbers and will not be described again.
- Apparatus 200A comprises six arrays of obstacles, namely arrays 214, 215, 216, 217, 218 and 219.
- Each of arrays 214-219 has the same number of obstacles, but the size of the obstacles increases in each successive array moving forward through separation chamber 202, such that the size of the passages between obstacles is decreased with each successive array, as fluid and particles progress through the chamber 202 in the forward direction F. Fluid flowing through the separation chamber 202 flows around and between the obstacles, the obstacles extending across the flow channel, being either fixed to, integral with or abutting the top and bottom surfaces of the flow channel.
- Apparatus 200A also comprises seven outlets 231 , 232, 233, 234, 235, 236 and 237 for removing separated particles from respective areas of chamber 202, and six additional inlets 221 , 222, 223, 224, 225 and 226 (in addition to sample inlet 220) for flushing separated particles out of outlets 231-237.
- Apparatus 200A also comprises an optional filter barrier 240 near each of the first and second ends 206 and 208 of chamber 202. Before interacting with the arrays of obstacles, the fluid flows around and between filter barrier 240.
- Each filter barrier 240 comprises a plurality of obstacles (filter-barrier obstacles) having a flat side facing the one or more arrays therein.
- the filter barrier obstacles are substantially semi-circular in cross-section, with a rounded side facing the carrier fluid channels 205, 207. Obstacles of the filter barrier 240 extend across the flow channel, being either fixed to, integral with or abutting the top and bottom surfaces of the flow channel.
- the filter-barrier obstacles are all of a same or similar size, and have a spacing, or gap, between adjacent filter-barrier obstacles which is small enough to prevent particles in chamber 202 from passing filter barriers 240. It is to be understood that filter barriers 240 are not required in all embodiments. For example, in some embodiments particles may be permitted to carrier fluid channels 205, 207 at either or both ends of apparatus 200A, or the individual channels of carrier fluid channels 205, 207 themselves may be small enough to prevent particles from entering.
- filter-barrier obstacles may be of any shape including teardrop- shape, posts, cup-shaped structures, V-shaped structures, trapezoid, funnel-shaped, square, round, elliptical, or other shapes. Corners of obstacles may be 'sharp' or may be rounded; an obstacle may have a combination of corner configurations.
- carrier fluid channels 205 and 207 at the ends of apparatus 200A each comprise a distribution network having a plurality of subchannels 242 in fluid communication with the chamber 202.
- the subchannels 242 by dispersing the fluid flow through multiple subchannel inlets when entering the separation chamber 202 provide for a more uniform velocity profile within the separation chamber 202, relative to a single inlet (which may provide a more parabolic velocity profile, where the fluid velocity along a longitudinal axis of the chamber 202 may be substantially greater than that along the sides of the chamber).
- the number of subchannels 242 is the same as the number of passages between obstacles in arrays 214-219, which is also the same number of gaps in filter barriers 240. Also, in the illustrated example, the subchannels 242, the gaps in filter barriers 240 and the passages between obstacles in arrays 214-219 are all aligned.
- Apparatus such as example apparatuses 200 and 200A may further comprise, or be in fluid communication with, and operationally linked to, one or more pumps, valves, fluid and/or sample reservoirs as are known in the art.
- Obstacles of arrays in the separation chamber may be of any suitable shape or configuration - the triangular obstacles shown in Figure 2, or the rounded triangles and trapezoids shown in Figure 2A are only examples.
- Other examples include teardrop- shape, posts, cup-shaped structures, V-shaped structures, trapezoid, funnel-shaped, square, round, parabolic, hemispherical, elliptical, or other shapes. Corners of obstacles may be 'sharp' or may be rounded; an obstacle may have a combination of corner configurations.
- an obstacle with a tapered shape, such as a triangle, trapezoid or teardrop may be suitable.
- the orientation of the narrow end of the obstacle with a tapered shape may be toward the first end of the flow channel; positioning of tapered obstacles adjacent to one another in the array provides for a funnel-shape formed therebetween.
- one or more of the obstacles within an array may be continuous with, or formed from, a side wall of the flow chamber.
- Figure 4 which is described in further detail below, illustrates a particular embodiment where an array of two obstacles, each continuous with a side wall of the flow channel form a funnel between them; the illustrated configuration in Figure 4 provides for a plurality of arrays, each array may be described as comprising two obstacles, or one funnel.
- the passages between obstacles of an array may be described by the pore size (W 0 ) (e.g., the width of the passage at the narrowest point of the passage) and the half- angle of the funnel taper ( ⁇ ), as illustrated schematically in Figures 3A and 3B.
- the array of obstacles are of a size and position to provide an array of funnel-shaped passages therebetween.
- the pore size - W 0 - may be selected depending on the size range of the particles in the sample, and the desired separation.
- the funnel- shaped passages may be parabolic or tapered, with concave, convex, convergent or divergent, stepped, or straight sides, at an angle defined by the half-angle of the funnel taper ⁇ .
- W 0 may be any suitable value from about 1 to about 20 ⁇ , or any amount therebetween, for example 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19 or 20 ⁇ , or any amount therebetween.
- the half-angle of the funnel taper ⁇ may be any suitable value from about 1 to about 30 degrees, or any amount therebetween; for example 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29 or 30 degrees, or any amount therebetween.
- the half-angle of the funnel is 5 degrees.
- the half-angle of the funnel is 10 degrees.
- the length of the funnel is dependent on the length of the obstacles forming the passage, and may be from about 10 to about 100 Mm, or any amount therebetween, for example 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 ⁇ , or any amount therebetween.
- arrays of obstacles may be separated by any suitable distance, for example from about 20 to about 200 ⁇ , or any amount therebetween, for example about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190 or 200 ⁇ , or any amount therebetween.
- the distance separating the arrays may be selected based on the volume or quantity of particles to be separated.
- the arrays may be spaced apart by different distances, or may all be spaced apart by the same distance.
- any number of arrays may be used within a separation chamber, selection of a suitable number will be within the ability of one skilled in the art, and dependent, in part, on the volume of sample, quantity of particles within a sample, and the number of different sizes or types of particles within a sample.
- a separation chamber may have from about 1 to about 20 arrays, or any amount therebetween, for example, , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19 or 20.
- the number of outlets from the separation chamber may be one greater than the number of arrays.
- extended microfluidic channels between, and in fluid communication with, one or more pumps or other pressure sources and the flow channel provide extra hydrodynamic resistance to allow for more precise control of flow through device when flow is controlled from a standard pressure source (see, for example, Figure 7, discussed below).
- fluid flow in a microfluidic system may be considered to be analogous to electrical circuits where the flow rate is equivalent to electrical current, pressure is equivalent to voltage, and hydrodynamic resistance is equivalent to electrical resistance.
- a selected hydrodynamic resistance may be calculated based on a selected fluid velocity of 100 ⁇ /s in the sorting area, at a selected pressure of 5 kPa.
- the selected flow rate and pressure are design constraints, and, the necessary hydrodynamic resistance is found using the formula:
- R H is the hydrodynamic resistance
- ⁇ the pressure drop
- Q the volumetric flow rate.
- the flow rate can be represented by:
- the width of the channel is w, and the height of the channel is h, while U is the velocity of the flow.
- hydrodynamic resistance can be calculated using: Where L is the length of the channel and the viscosity ⁇ of water is 10 "3 Pa s. The hydrodynamic resistance of the sorting area was assumed to be negligible in comparison to the resistance contribution from the additional channel length, so the total channel length needed was calculated based on the total amount of resistance needed.
- the carrier fluid may be any fluid that is compatible with both the polymer comprising the apparatus, and the particles to be separated or sorted. Where the particles are cells, the carrier fluid is generally an isotonic, aqueous solution with a pH from about 3 to about 10, or a pH from about 3, 4, 5, 6, 7, 8 or 9 to about 4, 5, 6, 7, 8, 9 or 10, or any amount therebetween. More particularly, the carrier fluid may have a pH from about 6.5 to 8.0, or any amount therebetween.
- the carrier fluid may be a buffer, for example phosphate buffered saline (PBS), Dulbecco's PBS, bicarbonate buffer, Tris, tricine, TAPS, HEPES, MOPS, PIPES, MES, SSC, Cacodylate or the like, or other biologically-compatible buffers as are known in the art. Where such a buffer needs to be prepared, one of skill in the art will be aware of standard reference documents that outline the necessary reagents, quantities, pH and other aspects necessary for proper handling.
- the carrier fluid may be isotonic saline.
- the carrier fluid may further comprise a surfactant, such as a biologically compatible surfactant.
- FIG. 7A shows an apparatus 700 according to another example embodiment.
- Apparatus 700 comprises a separation chamber 702 having a first end 706 and a second end 708.
- a first end carrier fluid control system 710 provides carrier fluid to first end 706 for generating flow in a forward direction F through chamber 702, and a second end carrier fluid control system 720 provides carrier fluid to second end 708 for generating flow in a reverse direction R through chamber 702.
- First end carrier fluid control system 710 comprises a forward pressure inlet channel 712 (which may be an extended serpentine microfluidic channel to provide additional hydrodynamic resistance) coupled to a pressure source (not shown).
- Forward pressure inlet channel 712 is in fluid communication with a first end distribution network 714 through a forward supply valve 713.
- Network 714 is also in fluid communication with an oscillation outlet 716 through an oscillation outlet valve 715.
- Oscillation outlet 716 provides a path for carrier fluid to leave chamber 702 during reverse flow, and may be in fluid communication with a reservoir or the like (not shown) for receiving carrier fluid.
- second end carrier fluid control system 720 comprises a reverse pressure inlet channel 722 (which may be an extended serpentine microfluidic channel to provide additional hydrodynamic resistance) coupled to a pressure source (not shown).
- Reverse pressure inlet channel 722 is in fluid communication with a second end distribution network 724 through a reverse supply valve 723.
- Network 724 is also in fluid
- Oscillation outlet 726 provides a path for carrier fluid to leave chamber 702 during forward flow, and may be in fluid communication with a reservoir or the like (not shown) for receiving carrier fluid.
- First and second end distribution networks 714 and 724 are in fluid communication with first end subchannels 718 and second end subchannels 728, respectively (see Figure 7B) for introducing carrier fluid into chamber 702.
- Apparatus 700 also comprises an inlet system 730 and an outlet system 740 on opposite sides of chamber 702.
- Inlet system 730 comprises a sample inlet 732 for introducing a sample of particles into chamber 702 near first end 706, and a flush fluid supply channel 734 in fluid communication with a plurality of additional inlets 736 for supplying carrier fluid to flush particles from chamber 702 after separation.
- An inlet valve 738 is operable to selectively open and close the connection between inlets 732, 736 and chamber 702.
- Outlet system 740 comprises a plurality of outlets 741-747 for removing particles from chamber 702.
- An outlet valve 748 is operable to selectively open and close the connection between outlets 741-747 and chamber 702.
- Figure 7B shows an example of the microstructure within chamber 702.
- a first filter barrier 751 is provided near first end 706 of chamber 702 for preventing particles in chamber 702 from entering subchannels 718.
- a second filter barrier 752 is provided near second end 708 of chamber 702 for preventing particles in chamber 702 from entering subchannels 728.
- a plurality of arrays of obstacles 761-766 are provided in chamber 702 between filter barriers 751 and 752.
- Figure 7C illustrates various dimensions of the microstructure, with g referring to the width of the gap between adjacent filter-barrier obstacles in filter barriers 751 and 752, W 0 referring to the pore size of the passages between adjacent obstacles of arrays 761-766, s referring to the distance between the centers of adjacent passages, I referring to the length of the passages and d referring to the distance between successive arrays.
- the passages between adjacent obstacles of arrays 761-766 become successively narrower moving forward through chamber 702 (e.g., W 0 is the largest for the passages of array 761 , and gets smaller with each successive array 762, 763, 764, 765 and 766).
- the number of outlets from the separation chamber is one greater than the number of arrays of obstacles within the separation chamber.
- inlets 732, 736 and outlets 741-747 may be substantially aligned with corresponding spaces between arrays 761-766 and filter barriers 751 , 752.
- sample inlet 732 and first outlet 741 are substantially aligned with the space between first filter barrier 751 and first array 752.
- one of the additional inlets 736 is substantially aligned with each of outlets 742-747, and with the spaces beyond each of arrays 761-766. Such an arrangement may facilitate flushing of separated particles from chamber 702.
- Figure 4 shows an example apparatus 400 for measuring the pressure difference required to deform single cells both ways through various sized funnel constrictions.
- Apparatus 400 comprises a control layer and a flow layer, which are indicated by vertical and horizontal fill patterns, respectively, as indicated by the legend in Figure 4.
- Apparatus 400 comprises generally a cell inlet portion 402, a funnel chain portion 404 and a pressure attenuator portion 406.
- Funnel chain portion 404 comprises a plurality of funnel constrictions (e.g., two sets of ten funnels) arranged in opposite polarity and decreasing in pore size towards the center of the funnel chain.
- Cell inlet portion 402 comprises first and second cell introduction zones 418 and 419 which are in fluid communication with either end of the funnel chain through valves 427 and 428.
- An example cell 430 is shown after introduction at 418, and moves into the funnel chain as indicated by arrow 431.
- Pressure attenuator portion 406 comprises a long microchannel 408 with ends 4 and 412.
- Microchannel 408 is in fluid connection at points 413 and 414 with branch channels 415 and 416, respectively, which are in turn connected to either end of funnel chain through valves 425 and 426.
- An external pressure applied across ends 411 and 412 results in an attenuated pressure across points 413 and 414 (and thus across the funnel chain when valves 425 and 426 are open) which is a fraction of the external pressure, the fraction determined by the ratio of the distance between points 413 and 414 to the distance between points 411 and 412.
- pressure attenuator portion 406 is configured to provide 1/100 of the applied external pressure to the funnel chain, but it is to be understood that a different fraction of external pressure may be provided in some embodiments. Also, in some embodiments, pressure attenuator portion 406 may be omitted (e.g., if a sufficiently finely controllable external pressure source is provided). Details of operation of apparatus 400 and example experiments are described below under the heading Example 4. .
- FIG. 4A shows an example apparatus 400A according to another embodiment.
- Apparatus 400A has a number of elements in common with apparatus 400 of Figure 4, which are identified with corresponding reference numbers and will not be described again.
- Apparatus 400A differs from apparatus 400 in that funnel chain portion 404 in apparatus 400A comprises five funnel constrictions 420, 421 , 422, 423 and 424 arranged in the same polarity, and in that there is no valve in branch channel 416.
- FIG. 4B shows an example apparatus 400B according to another embodiment.
- Apparatus 400B has a number of elements in common with apparatus 400 of Figure 4 and apparatus 400A of Figure 4A, which are identified with corresponding reference numbers and will not be described again.
- Apparatus 400B is substantially the same as apparatus 400A, except that funnel chain portion 404 in apparatus 400B comprises only a single funnel constriction 412.
- Apparatus such as example apparatuses 400, 400A and 400B may be operably connected to a variety of additional elements, such as, for example, pressure sources, controllers, and the like.
- apparatus 400, 400A and/or 400B may be coupled to a controllable pressure source and a controller conifigured to gradually increase pressure across a constriction until a particle passes through the constriction, and output the pressure required to force the particle through the constriction.
- the particle is a cell
- separation of one or more cell types or species from another in media, blood or other fluid has several applications.
- such applications may include leukapheresis, blood bank processing, separation of asynchronous cells in culture, enrichment of selected cell types (e.g. stem cells from cord blood or bone marrow or adipose tissue), and identification and/or enumeration of rare cell types (e.g. circulating tumor cells in the blood).
- Such circulating tumor cells may be of particular diagnostic, prognostic or clinical interest as markers of the development and extent of cancer and/or metastasis.
- Circulating tumor cells CTC demonstrate physical differences from other hematological cells, namely size and rigidity.
- WBCs white blood cells
- MSCs mesenchymal stem cells
- pluripotent stem cells pluripotent stem cells.
- PCR polymerase chain reaction
- Cells may be obtained from, or found within, for example, cell culture, an environmental sample, a subject's body fluids, or a tissue sample.
- Cells may be eukaryotic cells, including plant cells.
- a cell culture may be included in a process for isolating, enriching, or isolating and enriching one or more particular cell types or cell species.
- Tissue samples may be obtained by, for example, curettage, exfoliation, tissue scraping or swabbing, needle aspiration biopsy or needle (core) biopsy, incisional biopsy for sampling tissue, or excisional biopsy, which may entail total removal of the tissue of interest.
- Body fluids include, for example, blood, bone marrow, plasma, serum, sputum, urine, semen, amniotic fluid, cord blood, cerebrospinal fluid or the like.
- the deformability of cells is related to the composition of the cytoplasm and the structure of the cytoskeleton, and as a result, can vary by orders of magnitude depending on cell type and disease status.
- Cells may be obtained from, or found within, for example, cell culture, an environmental sample, a subject's body fluids, or a tissue sample.
- Cells may be eukaryotic cells, including plant cells.
- a cell culture may be included in a process for isolating, enriching, or isolating and enriching one or more particular cell types or cell species.
- Tissue samples may be obtained by, for example, curettage, exfoliation, tissue scraping or swabbing, needle aspiration biopsy or needle (core) biopsy, incisional biopsy for sampling tissue, or excisional biopsy, which may entail total removal of the tissue of interest.
- Body fluids include, for example, blood, bone marrow, plasma, serum, adipose tissue, sputum, urine, semen, amniotic fluid, cord blood, cerebrospinal fluid or the like.
- An environmental sample may comprise a fluid and one or more species of particle.
- the environmental sample may comprise fresh or salt water (e.g. seawater, lake water, water from a treatment facility, sewer outflow or other water samples) that may be acquired when monitoring a location or environment.
- the environmental sample may comprise soil, plant matter, or other matter that may be found when monitoring a location or environment.
- the environmental sample may comprise particles, such as those exemplified herein, including eukaryotic cells, and/or prokaryotic cells, and/or minerals, particulates or the like.
- a subject may be an animal, such as a mammal, reptile, bird or fish; examples of mammals include a rodent, cat, dog, primate, sheep, cow, pig, horse or ferret; examples of rodents include a mouse, rat, guinea pig or hamster; examples of primates include a human, a monkey, chimpanzee, rhesus macaque or green monkey.
- Examples of cells include red blood cells, white blood cells, peripheral blood mononucleocyte (PBMC), stem cells, tumor cells, cancer cells (primary or immortalized), animal or human cell lines (primary cell lines or immortalized cell lines) and the like.
- stem cells include adult stem cells, somatic stem cells, embryonic stem cells, non-embryonic stem cells, pluripotent stem cells, induced pluripotent stem cells, totipotent stem cells, multipotent stem cells, unipotent stem cells, hematopoetic stem cells, neural stem cells, mesenchymal stem cells, endothelial stem cells, and the like Cancer cells may be from any type of cancer or tumor.
- Non-limiting examples of different types of cancers and tumors include: carcinomas, such as neoplasms of the central nervous system, including glioblastoma, astrocytoma, oligodendroglial tumors, ependymal and choroid plexus tumors, pineal tumors, neuronal tumors, medulloblastoma, schwannoma, meningioma, and meningeal sarcoma; neoplasms of the eye, including basal cell carcinoma, squamous cell carcinoma, melanoma, rhabdomyosarcoma, and retinoblastoma; neoplasms of the endocrine glands, including pituitary neoplasms, neoplasms of the thyroid, neoplasms of the adrenal cortex, neoplasms of the
- neoplasms of the gastroenteropancreatic endocrine system neoplasms of the gonads
- neoplasms of the head and neck including head and neck cancer, neoplasms of the oral cavity, pharynx, and larynx, and odontogenic tumors
- neoplasms of the thorax including large cell lung carcinoma, small cell lung carcinoma, non-small cell lung carcinoma, malignant mesothelioma, thymomas, and primary germ cell tumors of the thorax; neoplasms of the alimentary canal, including neoplasms of the esophagus, stomach, liver, gallbladder, the exocrine pancreas, the small intestine, veriform appendix, and peritoneum, adneocarcinoma of the colon and rectum, and neoplasms of the anus; neoplasms of the genitourinary tract, including renal cell carcinoma, neoplasms of the renal pelvis, ureter, bladder, urethra, prostate, penis, testis; and female reproductive organs, including neoplasms of the vulva and vagina, cervix, adenocarcinoma of the uterine corpus,
- neoplasms of the hematopoietic system including myelodysplastic sydromes, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, HTLV-I and T-cell leukemia/lymphoma, chronic lymphocytic leukemia, hairy cell leukemia, Hodgkin's disease, non-Hodgkin's lymphomas, and mast cell leukemia; and neoplasms of children, including acute lymphoblastic leukemia, acute myelocytic leukemias, neuroblastoma, bone tumors, rhabdomyosarcoma, lymphomas, renal tumors, and the like.
- An apparatus comprising such an apparatus, or methods according to various embodiments of the invention provide cell- handling capabilities for sorting and capturing a subpopulation of cells in a format which allows for subsequent manipulation and/or analysis.
- Such a system may allow for selection of a single cell from a population, the capture of this cell at any position within an addressable array of chambers, the application of one or more reaction conditions, and imaging of each reaction chamber.
- This functionality may provide an instrument for chemical genetics studies of a plurality of single cells. Examples of cell- based microfluidic assays are described in, for example PCT Publication WO 98/00231 and WO 98/45481. Cell-based microfluidic assays may be useful for screening of binding and/or internalization of cell ligands, for example, receptor ligands, drugs, cofactors and the like.
- a cell or cells may be subjected to further analysis, for example nucleic acid sequencing, nucleic acid amplification, protein extraction or isolation, fluorescent in situ hybridization, immunostaining, patch-clamping, calcium flux measurements, whole cell electrophoresis, or any of several methods of cell analysis known in the art. Additionally, the capture and imaging of one or a few single cells in microfabricated devices may be used to monitor cellular response to varying concentrations of one or a few chemical stimuli.
- Nucleic acid may be extracted from cells separated from a heterogenous mixture, and the nucleic acid subjected to sequence analysis. Alternatively, a target nucleic acid within the cell may be specifically identified using a probe, or specifically amplified using one or more primers.
- a target nucleic acid is a nucleic acid comprising one or more sequences of interest.
- the presence of a target nucleic acid in a sample or reaction mixture may be detected, and depending on the assay design, may also be quantified.
- the target nucleic acid may be DNA, for example genomic DNA, extrachromosomal DNA, mitochondrial DNA, cDNA or the like.
- the target nucleic acid may be RNA, for example mRNA, RNAi, miRNA, hnRNA or the like.
- the target nucleic acid may comprise a polymorphism.
- Detection of particular cell types within a body fluid may be useful in determining the state of a pathology of a subject.
- a subject diagnosed with a tumor may have their blood, plasma or serum periodically tested by passaging such body fluid through an apparatus according to various embodiments herein. Larger and/or more rigid cells may be subsequently analyzed for their nucleic acid complement, protein or polypeptide complement. Detection of circulating tumor cells in the blood or plasma or lymph of a subject may be indicative of an early stage of metastasis.
- the pressure of the carrier fluid in the forward and reverse flows may be regulated by one or more pumps or similar devices to controllably push fluid through the flow chamber in a unidirectional or an oscillating manner.
- the carrier fluid is driven through a conduit, into an inlet and through a distribution network into the flow
- Valves operate to contain the
- a sample comprising particles is placed into a separation area in the flow channel/separation chamber via a sample inlet; additional carrier fluid or buffer may be provided via the sample inlet, or one or more separate buffer inlets, at a desired rate or volume.
- the sample may be introduced into the separation area before carrier fluid is introduced; alternately the separation chamber may be flushed by carrier fluid in advance of introduction of the sample.
- the length of time of the forward flow and reverse flow may be the same, or may be different.
- the forward flow may be of a longer duration than the reverse flow or the reverse flow may be of a longer duration than the forward flow.
- the forward and reverse flow pressures are non-zero, and may be of the same pressure, or may be different.
- the pressure of the forward flow may be greater than the reverse flow, or the pressure of the reverse flow may be greater than the forward flow.
- the forward or reverse flow may independently be from about 0.1 to about 10 seconds in duration; or from about 0.1 , 0.5, 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 seconds in duration, or any amount therebetween.
- the pressure of the forward or reverse flow may independently be from about 1 kPa to about 50 kPa, or any amount therebetween, for example 1 , 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 kPa, or any amount therebetween.
- a 'rest' period is included in the cycle, it may be of any duration from about 0.5 to about 10 seconds in duration; or from about 0.5, 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 seconds in duration, or any amount therebetween.
- the number of cycles of oscillation may be from about 1 to about 20, or any amount therebetween, for example 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19 or 20, or any amount therebetween.
- outlets may be opened simultaneously, or independently (by release of one or more valves) and the particles in the corresponding regions between arrays flushed out by additional carrier fluid introduced either by the distribution array, or via the sample inlet or buffer inlet(s). New cell samples may then be introduced through the sample inlet and the process may be repeated multiple times to separate large volumes of cells.
- Multilayer soft lithography is a well-known fabrication technique that allows for facile and robust fabrication of microfluidic devices having hundreds to thousands of microscopic reaction chambers, valves, pumps, fluidic logic elements and other components.
- MSL Multilayer soft lithography
- MSL multilayer soft lithography
- PDMS polymers
- Thin and thick layers of PDMS with stoichiometric ratios of base and hardener, respectively less and higher than 10:1 are formed on separate wafers.
- a thinner layer may be obtained using a base:hardener ratio of 20: 1 and spun onto a silicon wafer substrate.
- a thicker layer may be obtained using a base: hardener ratio of 5: 1.
- Photoresist patterns previously made on the wafers will define the microfluidic channels of the device.
- the thick layer is then peeled away from the wafer and placed on top of the thin wafer. After baking, the excess components in each layer will bond and form a PDMS 'chip' composed of two layers of channels.
- Methods of working with elastomers and applying them in microfluidic applications are known in the art; see, for example, U.S. Pat. No. 6,929,030; Scherer et al. Science 2000, 290, 1536-1539; Unger et al. Science 2000, 288, 113- 116; McDonald et al. Ace. Chem. Res. 2002, 35, 491-499; Thorsen, T. et al,.
- Various polymers including but not limited to plastics and soft polymers, may be used in microfluidic devices and systems.
- Examples of polymers that may be useful in fabrication of all, or a portion of a microfluidic device according to various aspects of the invention include elastomers.
- Elastomers may be generally characterized by a wide range of thermal stability, high lubricity, water repellence and physiological inertness. Other desirable characteristics of elastomers may vary with the application. It is within the ability of one of skill in the art to select a suitable elastomer or combination of elastomers for the desired purpose.
- elastomers examples include silicone, polydimethylsiloxane (PDMS), photocurable perfluoropolyethers (PFPEs), fluorosilicones, polyisoprene, polybutadiene, polychloroprene, polyisobutylene, polyurethanes, poly(styrene-butadiene- styrene), vinyl-silane crosslinked silicones, and the like.
- Polymers may be optically clear, or may be opaque, or have varying degrees of transparency. In some embodiments of the invention, it may be desirable to use a biocompatible elastomer.
- PDMS is one of the first developed and more widely used elastomers in soft lithography applications.
- Photoresist patterns laid out on a silicon wafer or other suitable support provide a mold for casting the layers.
- photoresists may be categorized as positive or negative.
- Positive photoresist are capable of very fine resolutions. They are highly soluble in alkaline solutions such as OH; however, photosensitive dissolution inhibitors such as diazonaphthaquinone (DQ) are typically used to block this effect.
- DQ diazonaphthaquinone
- a photoreaction with ultraviolet (UV) light destroys the DQ and allows the photoresist to be dissolved by the developer solution. The idea of processing this type of photoresist is that all sections exposed to UV light will be removed.
- An example of a positive photoresist is SPR220-7 (Shipley Company LLC).
- Negative photoresist generally comprises a non-photosensitive substrate, a photosensitive cross-linking agent, and a coating solvent. Upon exposure to UV light, the cross- linking agent is activated and causes a hard epoxy to form. The remaining unexposed sections of the photoresist are washed away with the developer solution.
- SU8 MicroChem
- SU8 as an epoxy is very strong and can resist subsequent
- photolithography processes Detailed methods and techniques for working with particular photoresists are available from the various manufacturers, and are not addressed further herein. Examples of particular photoresists are for illustrative purposes only, and are not to be considered as limiting of the present invention.
- microfluidic device may be incorporated into the microfluidic device during fabrication - hydrodynamic resistance (e.g. serpentine extensions of the channel linking the pump and the separation area to provide additional precision and control of the oscillation pressures), micron-scale valves, pumps, channels, fluidic multiplexers, perfusion chambers and the like may be integrated during MSL. Methods of making and integrating such components are described in, for example, US Patent Nos. 7,144,616, 7,113,910, 7,040,338, 6,929,030, 6,899,137, 6,408,878, 6,793,753, 6,540,895; US Patent Applications 2004/0224380, 2004/0112442; PCT Applications WO 2006/060748.
- one or more surfaces of a flow channel, via or other space within the microfluidic apparatus may be treated or coated with a surface treatment agent.
- the surface treatment agent may be a non-biofouling agent.
- surface treatment agents may include hydrophilic or hydrophobic compositions, charged, or immunobinding agents, polymers, BSA, or the like that may aid in fluid flow (e.g. reduce fluid friction and/or flow resistance) or prevent the adherence of hydrophobic or hydrophilic components in the carrier fluid or sample, or reduce particle interaction with a surface of the flow chamber, or elements therein such as obstacles, fluid barriers or the like.
- polymers include polyethylene glycol of varying polymer MW, such as are available in the art.
- the channel, via or other space may be temporarily filled with a fluid comprising a surface treatment agent (e.g. to prevent or reduce non-specific adhesion of particles, particularly cells).
- a surface treatment agent e.g. to prevent or reduce non-specific adhesion of particles, particularly cells.
- One of skill in the art will be able to select a suitable polymer size and concentration to deposit sufficient polymer or protein on the surface, while maintaining a suitable viscosity to allow for handling and fluid flow within the device when preparing the treatment.
- the flow channel, via or other space may be flushed with a second fluid (e.g. a buffer, media, PBS or the like) to remove any leftover BSA or polymer.
- a second fluid e.g. a buffer, media, PBS or the like
- the silicon masters were fabricated in a two-step photolithographic process. First, the silicon wafer was coated with a layer of SU-8 negative photoresist
- the wafer was then baked on a 95°C hotplate for 5 minutes and subsequently exposed to UV light through an optical photomask, which was designed using SolidworksTM DWGEditor and commercially- produced by Advance Reproductions (Andover, MA). After exposure, the wafer was then baked at 65°C, 95°C, then 65°C for 1 , 4, and 1 minutes respectively.
- the patterned wafer was developed in SU-8 developer (Microchem) and washed with isopropanol. To harden the patterned microstructures, the wafer was then baked at 200°C for a period of one hour.
- the final bake temperature was reached by a slow ramp at a rate of 10 degrees every 12 minutes. After baking, the wafer was allowed to equilibrate to room temperature on top of the hotplate.
- SPR220-7.0 photoresist (Microchem) was added to the cooled wafer by spin coating at 600 rpm for 50s. Following spinning, the edge bead was removed from the wafer manually and then softbaked for 1 , 5 and 1 minutes at 65°C, 95°C, and 65°C respectively.
- a second photomask (CAD/Art Designs) was aligned to the previous set of patterns and subsequently exposed and developed in MF 319 developer (Microchem).
- the wafer was baked on a 95 °C hotplate for 5 minutes to allow the SPR220-7.0 photoresist layer to reflow and take on a parabolic profile. Great care is taken throughout the process to prevent exposure of the wafer to thermal shocks which can cause the micro-scale SU-8 features to warp and bend.
- the fluid control layer was fabricated on a second silicon master using a single layer of SPR 220-7.0 using the same procedure as described above.
- the PDMS masters were fabricated using standard multi-layer soft lithography techniques as are known in the art for example, as described by Unger et al. 2000 (Science 288: 13) and Studer et al. 2004 (Journal of Applied Physics 95:393). Two layers were formed with a 5:1 base to hardener ratio of RTV 615 silicone (Momentive Performance Materials) for the flow layer and a 20:1 ratio for the control layer. The layers were bonded by diffusion and attached to a glass slide following 45 seconds in an oxygen plasma (Herrick Plasma). Inlets and outlets were punched manually using a 0.5 mm punch (Technical Innovations). A solution of 1% BSA in PBS was used to fill the device prior to operation and incubated for 10 minutes to prevent nonspecific adsorption of cells onto the PDMS surface.
- RTV 615 silicone Momentive Performance Materials
- PBMCs Peripheral blood mononuclear cells
- CBR Centre for Blood Research
- L1210 mouse lymphoma cells were obtained from culture.
- MLCs were cultured in suspension using RPMI 1640 (GibcoTM, InvitrogenTM) with 10% fetal bovine serum and 1 % penicillin/streptomycin kept inside an incubator held at 37°C with 100% humidity and 5% C0 2 .
- the cells Prior to experimentation, the cells were concentrated via centrifugation and re- suspended in a solution of phosphate buffered saline (PBS) containing 0.4% bovine serum albumin (BSA) at a concentration of 1 x 10 7 cells/ml. Cells were used for experimentation 3-4 days after passaging. In experiments where cells were stained, the L3224 LIVE/DEAD Viability/Cytotoxicity kit (Invitrogen) was used according to the manufacturer's directions. Peripheral blood mononuclear cells were prepared from whole blood obtained from healthy volunteers. Whole blood was drawn into 6 ml sodium heparin containing tubes.
- PBS phosphate buffered saline
- BSA bovine serum albumin
- PBMCs were separated out using Histopaque 1077 (Sigma-Aldrich) according to the manufacturer's instructions, and then re-suspended at a concentration of 1 x 10 7 cells/ml in AIM 5 media (GIBCO-lnvitrogen).
- the pressure differential required to deform single cells was determined using a microfluidic device disclosed herein.
- the apparatus used in conducting the particle size is illustrated in Figure 4.
- Using many funnels in one microchannel enables experiments with varying funnel geometries to be conducted on the same cell, while mirroring the funnel chain design at the center of the microchannel eliminates any possible
- the chain of funnels is connected to parallel microchannel networks for introducing individual cells from a sample reservoir and for applying an attenuated pressure across the funnel chain. These two networks are isolated from each other using microvalves 425, 426, 427 and 428 so that the introduction of cells and the pressure deformation process can take place independently. Pressure attenuation is accomplished using a fluidic circuit similar to a resistive-divider used in electronic circuits. As shown in Figure 4, pressure from an external source is applied across points 41 1 and 412 on a long, possibly serpentine, microchannel. Side branches located at points 413 and 414 are spaced at 1/100 of the distance from 41 1 to 412, and therefore attenuate the applied pressure by a factor of 100. Microchannel networks connected to the side branch do not significantly affect the pressure drop across 413 and 414 as long as the hydrodynamic resistance of the network is significantly greater than that of the microchannel segment between 413 and 414.
- microstructures were measured using the following process: A single cell was introduced into the main microchannel with valves 425 and 426 sealed, and valves 427 and 428 open. Once the cell flows into the funnel region, the states of all four valves were inverted, exposing the funnel array to the attenuated pressure applied across 413 and 414. This pressure was raised gradually in increments of 5 Pa until the cell successfully transited through successive constrictions. After traversing through a given funnel constriction, the pressure was released and the cell was then given -30 s to recover its original shape before taking a subsequent measurement. Valves and flow within the device were all pressure-controlled using a combination of custom-built apparatus and a commercial pressure controller (FluigentTM). Experimental data was collected visually on an inverted microscope (NikonTM Ti-U) with a CCD camera (Nikon DS-2MBW). Static measurements were taken using the image capture software supplied with the camera (Nikon NIS-Elements).
- [00128]MLCs with cell diameters (cp ce u) ranging from 8 to 12 ⁇ , were used to study the performance of the funnel ratchet.
- the forward and reverse threshold pressures required to squeeze single cells through funnel constrictions tapered at 10° plotted as a function of pore size (W 0 ) are shown in Figure 5(a).
- the asymmetry between the forward and reverse threshold pressure required for ratcheting is clearly observed.
- the measured threshold pressures were remarkably repeatable for the same cell, which suggests that this device could be used to study single cell biomechanics in a fashion similar to micropipette aspiration (Hochmuth, R.M., Micropipette aspiration of living cells. Journal of Biomechanics, 2000.
- the resulting value for the cortical tension of MLCs is 750 ⁇ / ⁇ , which is comparable with values obtained for mammalian eukaryotic cells in previous studies using micropipette aspiration (Tinevez, J.Y., et al., Role of cortical tension in bleb growth. Proc. Natl. Acad. Sci. U.S.A., 2009. 106(44): p. 18581-18586).
- the pressure asymmetry results measured from the deformation of MLCs are shown in Figure 5(b) as a non-dimensional plot of the reverse- to-forward pressure ratio (P R /P F ) versus the cell-diameter-to-funnel-opening ratio ((p C eiiM/ 0 ) for funnel constrictions tapered at 10°, 5°, and 0°.
- P R /P F reverse- to-forward pressure ratio
- (p C eiiM/ 0 ) cell-diameter-to-funnel-opening ratio
- the average asymmetry values for the 5° funnel and the 10° funnel are approximately 1.8 and 1.5 respectively.
- the 0° funnel was a 20 ⁇ long rectangular slot constriction. Deforming cells through these control constrictions showed no pressure asymmetry (P R /P F ⁇ 1.0), which confirmed the lack of inherent asymmetries in the measurement apparatus.
- a serial array of funnel constrictions may be used in an apparatus for measuring the stiffness of individual particles or cells.
- stiffness it may be absolute, and derived from the pressure required to push the cell through the funnel, or may be relative to a control particle or cell with a defined stiffness.
- FIG. 6(a) The displacements of single MLCs in a funnel chain for several different amplitudes of the square-wave oscillatory pressure are shown in Figure 6(a).
- the funnel pore size in this device is 6 ⁇ , while the pressure oscillation frequency is 0.5 Hz.
- This graph also includes cell displacement data from a control experiment where the oscillatory pressure was applied to a MLC in a section of the central microchannel prior to entering the funnel chain.
- the unbiased sinusoidal cell displacement shown here confirms the unbiased oscillatory fluid flow of the bulk fluid.
- Ratcheting behavior was observed when the pressure amplitude exceeded the threshold required to deform MLCs across a single funnel constriction along the direction of the taper. Specifically, at an amplitude of 100 Pa, cells were confined to oscillate in the region between two funnels, but at 200 Pa and above, the cell began to ratchet forward in the funnel chain in a reliable and deterministic fashion, as shown in Figure 6(a). The observed threshold for ratcheting was consistent with the forward and reverse pressure thresholds shown in Figure 5(a), which are 165 Pa and 220 Pa respectively for
- the ratcheting behavior was found to depend on oscillation frequency as shown in Figure 6(b). At a frequency of 1 Hz and an amplitude of 150 Pa, the cells do not have sufficient time to traverse the region between the funnels ( ⁇ 50 pm) and also deform across the funnel. Ratcheting transport was enabled at 0.5 Hz, and proceeded at an increased net forward velocity at 0.333 Hz, suggesting that ⁇ 0.5 s was required to complete the process to deform through the funnel constriction. Additionally, the ratcheting process was also dependent on the synchronization between the applied pressure and the location of the cell in a funnel constriction, as well as surface forces between the cell and the microstructure.
- Apparatus such as example apparatuses 200, 200A and 700 described above with reference to Figures 2, 2A and 7 may also be used for particle deformability analysis.
- a population of cells may be infused into a separation chamber and separated according to deformability as described herein, with cells of different deformabilities removed from different outlets. The number of cells removed from each outlet may be used to determine a characteristic deformability distribution in order to evaluate the morphology of the cell population.
- a cell separation apparatus comprising 128 funnels across the width of the separation area in 12 horizontal rows was fabricated.
- the gap g between filter-barrier obstacles is 2 ⁇
- the length I of the passages (and obstacles) in each array is 50 ⁇
- the distance d between arrays is 50 pm
- the inlet channel between filter barrier 750 at the first end and the first array 761
- the separation s is 25 m.
- Valves 738 and 748 placed to the left and right (directional references refer to the example orientation on the drawing sheet containing Figure 7A) of the separation chamber 702 are used to isolate the loading procedure from the separation procedure. This arrangement provides a purely horizontal flow during loading and purely vertical flow during separation. Valves 713, 715, 723 and 725 above and below the separation chamber are used to quickly switch between forward and backward flow. An oscillating flow is used within the separation area to reduce the occurrence of clogging, biofouling, and inconsistent sorting resulting from cytoskeleton remodeling.
- the operation of the device has two stages, a filling stage and a sorting stage.
- valves 713, 715, 723 and 725 are closed and equal pressures are applied to both the cell inlet 732 and additional inlets 736 such that the flow is horizontal through the sorting area and cells fill the space (or "row") between the first array 761 and first filter barrier 751.
- valves 738 and 748 are closed, sealing off the sorting area.
- a constant pressure is applied to both the forward and reverse pressure inlet channels 712 and 722.
- Valves 713, 715, 723 and 725 act as a fluidic H bridge enabling precise control of the oscillation duration and frequency.
- a forward pressure for 3 seconds followed by a reverse pressure for 1 second was employed, enabling a forward biased motion of the cells through the sorting area.
- the forward and reverse pressures are equal, and gently deform the cells through the funnel openings as they travel forward through the device.
- valves 713, 715, 723 and 725 are closed while valves 738 and 748 are opened. This begins the filling stage again, and while the bottom row is filled with new cells, the previously sorted cells are pushed to the right into separate outlets above by the incoming PBS. This process repeats until as many cells as desired have been sorted.
- filter barriers are placed on either end, or both ends of the separation area within the flow chamber.
- the blocks employed in the experiments described herein have a semicircular profile so that any cell which may pass outside of the separation area may more easily squeeze back when the opposite pressure is applied.
- serpentine microfluidic channels at both ends of the flow channel provide additional hydrodynamic resistance in order to ensure that fluid flow through the apparatus is controlled from a standard pressure source.
- PBMCs and MLCs were chosen to validate the operation of the device due to the fact that they have similar but not overlapping size distributions.
- PBMCs were measured to have a mean diameter of 7.2 ⁇ with a standard deviation of 0.6 ⁇ , whereas the mean diameter of MLCs was measured to be 11.1 ⁇ with a standard deviation of 1.2 ⁇ ⁇ .
- MLCs was measured to be 11.1 ⁇ with a standard deviation of 1.2 ⁇ ⁇ .
- FIG. 8A This illustrates a clear separation between the two cell populations within the device, with the peak of the MLC distribution occurring at a funnel opening size of about 9-10 ⁇ and the peak of the PBMC distribution at about 6 ⁇ .
- the sorting area is large enough that only a single cell becomes caught in each funnel, and the smaller cells easily pass through to the smaller funnel rows.
- the MLCs were stained with simple cell stain (Calcein AM, Invitrogen) to clearly differentiate them from the PBMCs.
- FIG. 8B and 8C A micrograph of the distribution both in brightfield and under fluorescence is shown in Figures 8B and 8C. Only the MLC population is visible under fluorescence, while both populations of cells can be seen in the brightfield. Since each row is essentially may have a separate outlet, the separation boundary can be chosen at any pore size to yield the best separation efficiency. In this particular example, a pore size of 8 ⁇ was used as a 'cut-off' between the two cell populations.
- Figure 8D shows a high separation efficiency achieved using the apparatus and cut-off value, with 98% of the MLCs caught in the rows with a pore size of greater than 8 ⁇ ("Trapped at 8-14 ⁇ m")and 97% of the PBMCs in the rows with a pore size of less than 8 ⁇ ("Trapped at 2-7 ⁇ ").
- FIG. 11 shows the evolution of a MLC distribution after 0, 2, 4 and 6 oscillations, and a steady state distribution which did not change after 20 oscillations. The entire system reaches steady state after approximately 5 oscillations which corresponds to 20 seconds using an oscillation period of 4 seconds.
- the oscillation period was varied by changing the forward direction time.
- the backward, or reverse time was left at 1 second to allow the MLCs sufficient time to recover their original shape after being deformed into a funnel, and forward times of 2, 3, 6 and 8 seconds were employed.
- Figure 13 shows the distribution of cells according to funnel size for the various forward time oscillations. It can be seen that for forward times longer than 3 seconds, no significant difference was observed in the MLC distribution. However at 2 seconds, the cells did not have sufficient time to deform through the funnel pores and remained caught in larger funnel rows.
- the mechanism whereby the cells transit through this device is a ratcheting mechanism.
- the pores are asymmetrically shaped such that less pressure is required for a cell to transit forward than backward through the opening.
- a sample containing MLCs was brought to steady state after one minute with an oscillation period of 3 seconds forward and 1 second backward. This was then immediately reversed by oscillating at 1 minute with a period of 3 seconds backward and 1 second forward.
- Figure 14 shows the percentage of cells that did not return to their original position, but remained caught at various stages in the apparatus, corresponding to the pore size they were unable to traverse. With a pressure of 10.3 kPa applied, over 50% of the cells exhibit ratcheting, and this percentage increases up to 100% with an applied pressure of 41.4 kPa.
- Example 6 Red blood cell deformability analysis
- red blood cells are toroid or disc-shaped, rather than generally spherical, in the absence of movement restriction, they may progress through the device as a 'flat' disk (e.g. sideways), or On edge' (substantially upright, like a wheel).
- a channel with a height of about 2-3 ⁇ or less will confine the majority of red blood cells to migrate as a 'flat disk, while a channel with a height greater than about 3-4 ym will allow the red blood celt to migrate in either configuration, or folded or at an angle.
- the apparatus was configured to provide a channel depth of about 3 ⁇ , which confines the cell to move flat into the funnel, not to stand up and fold as it traverses through.
- the threshold pressure required to push the cell through the funnel is measured as an indicator of the whole cell rigidity or deformability.
- the minimum applied pressure differential is -0.3 Pa. Accordingly, the cortical tension of the cell can be measured based on the information of the cell radius, funnel geometry and measured threshold pressure, as governed by equation (1 ) above derived from Laplace law
- [00157JPMS phenazine methosulfate
- RBC sickled red blood cell
- the cell membrane stiffens. This induced stiffening may be employed to simulate the microrheologic properties of dense and/or dehydrated sickle cells (Hebbel, R.P., A. Leung, and N. Mohandas, Oxidation-Induced Changes in
- RBCs were suspended at 20% hematocrit in balanced salt solution with antibiotics. The RBC suspensions were then modified with 0, 10, 25, and 50 ⁇ PMS for 60 minutes, followed by dilution 200:1 using phosphate buffered saline for use with the apparatus.
- Embodiments of the disclosure can be represented as a computer program product stored in a machine-readable medium (also referred to as a computer-readable medium, a processor-readable medium, or a computer usable medium having a computer-readable program code embodied therein).
- the machine-readable medium can be any suitable tangible, non-transitory medium, including magnetic, optical, or electrical storage medium including a diskette, compact disk read only memory (CD-ROM), memory device (volatile or non-volatile), or similar storage mechanism.
- the machine- readable medium can contain various sets of instructions, code sequences, configuration information, or other data, which, when executed, cause a processor to perform steps in a method according to an embodiment of the disclosure.
Landscapes
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Dispersion Chemistry (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014504129A JP5990256B2 (en) | 2011-04-15 | 2012-04-13 | Particle separation method and apparatus |
AU2012243396A AU2012243396A1 (en) | 2011-04-15 | 2012-04-13 | Method and apparatus for separation of particles |
US14/112,021 US9880084B2 (en) | 2011-04-15 | 2012-04-13 | Apparatus for separation of particles |
CA2833026A CA2833026A1 (en) | 2011-04-15 | 2012-04-13 | Method and apparatus for separation of particles |
EP12771679.3A EP2697357A4 (en) | 2011-04-15 | 2012-04-13 | Method and apparatus for separation of particles |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161476151P | 2011-04-15 | 2011-04-15 | |
US61/476,151 | 2011-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012139209A1 true WO2012139209A1 (en) | 2012-10-18 |
Family
ID=47008741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2012/000362 WO2012139209A1 (en) | 2011-04-15 | 2012-04-13 | Method and apparatus for separation of particles |
Country Status (6)
Country | Link |
---|---|
US (1) | US9880084B2 (en) |
EP (1) | EP2697357A4 (en) |
JP (1) | JP5990256B2 (en) |
AU (1) | AU2012243396A1 (en) |
CA (1) | CA2833026A1 (en) |
WO (1) | WO2012139209A1 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014150928A1 (en) * | 2013-03-15 | 2014-09-25 | The Regents Of The University Of California | Devices for sorting cells in a sample and methods for use thereof |
EP2790020A3 (en) * | 2013-03-15 | 2014-12-24 | Parsortix, Inc. | Methods for segregating particles using an apparatus with a size-discriminating separation element having an elongate leading edge |
JP2016097121A (en) * | 2014-11-21 | 2016-05-30 | ラトックシステムエンジニアリング株式会社 | Method and program for evaluating network |
CN106164658A (en) * | 2014-02-10 | 2016-11-23 | 泰克年研究发展基金会公司 | For cell separation, the method and apparatus that grows, replicate, operate and analyze |
US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
US9580678B2 (en) | 2013-06-21 | 2017-02-28 | The Regents Of The University Of California | Microfluidic tumor tissue dissociation device |
WO2017043862A1 (en) * | 2015-09-07 | 2017-03-16 | 주식회사 엘지화학 | Apparatus for delaminating sheet material |
US9695212B2 (en) | 2012-12-13 | 2017-07-04 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
US9724408B2 (en) | 2013-05-18 | 2017-08-08 | Aduro Biotech, Inc. | Compositions and methods for activating stimulator of interferon gene-dependent signalling |
US9770467B2 (en) | 2012-06-08 | 2017-09-26 | Aduro Biotech, Inc. | Compositions and methods for cancer immunotherapy |
US9782707B2 (en) | 2014-03-24 | 2017-10-10 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US9796166B2 (en) | 2014-03-24 | 2017-10-24 | Fenwal, Inc. | Flexible biological fluid filters |
WO2017196037A1 (en) * | 2016-05-11 | 2017-11-16 | 주식회사 엘지화학 | High pressure homogenizer and method for manufacturing graphene using same |
US9840533B2 (en) | 2013-04-29 | 2017-12-12 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
US9968738B2 (en) | 2014-03-24 | 2018-05-15 | Fenwal, Inc. | Biological fluid filters with molded frame and methods for making such filters |
US10159778B2 (en) | 2014-03-24 | 2018-12-25 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US10176292B2 (en) | 2013-07-31 | 2019-01-08 | Memorial Sloan-Kettering Cancer Center | STING crystals and modulators |
US10376627B2 (en) | 2014-03-24 | 2019-08-13 | Fenwal, Inc. | Flexible biological fluid filters |
US10722540B1 (en) | 2016-02-01 | 2020-07-28 | The Regents Of The University Of California | Microfluidic device and method for shear stress-induced transformation of cells |
US10926257B2 (en) | 2017-08-28 | 2021-02-23 | The Regents Of The University Of California | Microfluidic device for the digestion of tissues into cellular suspensions |
US11524293B2 (en) | 2018-01-17 | 2022-12-13 | Sartorius Stedim North America Inc. | Cell separation device, method and system |
US11579073B2 (en) | 2017-02-07 | 2023-02-14 | Nodexus Inc. | Microfluidic system with combined electrical and optical detection for high accuracy particle sorting and methods thereof |
US11873319B2 (en) | 2013-05-03 | 2024-01-16 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type I interferon |
US12038438B2 (en) | 2008-07-18 | 2024-07-16 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
US12036550B2 (en) | 2017-08-28 | 2024-07-16 | The Regents Of The University Of California | Microfluidic device for the digestion of tissues into cellular suspensions |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2996582A1 (en) * | 2015-08-31 | 2017-03-09 | I Peace, Inc. | Pluripotent stem cell manufacturing system and method for producing induced pluripotent stem cells |
US11474023B2 (en) * | 2017-06-02 | 2022-10-18 | The General Hospital Corporation | Oscillatory focusing of particles in channels |
US20190071627A1 (en) * | 2017-08-04 | 2019-03-07 | Ecole Polytechnique Federale De Lausanne (Epfl) | Micro-Fluidic Particle Concentrator and Filtering Device |
US20210187508A1 (en) * | 2017-10-16 | 2021-06-24 | 1 CellBio ,Inc. | Systems and methods for particulate encapsulation in microdroplets |
CN109797101B (en) * | 2017-11-17 | 2022-03-04 | 北京中源合聚生物科技有限公司 | Cell reactor microcarrier cell harvesting and reseeding amplification method |
US20210008554A1 (en) * | 2018-02-16 | 2021-01-14 | Astrego Diagnostics Ab | Cell capture in microfluidic devices |
EP3647405A1 (en) * | 2018-11-02 | 2020-05-06 | Microfluidx | Cell culture device and method of using the same |
EP3986358A4 (en) * | 2019-06-20 | 2023-06-21 | Amniotics AB | An apparatus for filtering amniotic fluid |
WO2021113807A1 (en) * | 2019-12-06 | 2021-06-10 | The University Of North Carolina Atchapel Hill Office Of Technology Commercialization | Wedge chamber device for mouting samples for microscopy |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060051265A1 (en) | 2004-09-08 | 2006-03-09 | Health Research, Inc. | Apparatus and method for sorting microstructures in a fluid medium |
WO2007021409A1 (en) * | 2005-08-11 | 2007-02-22 | University Of Washington | Separation and concentration channel with determined pore shape |
US20070161051A1 (en) * | 2006-01-12 | 2007-07-12 | Biocept, Inc. | Device for cell separation and analysis and method of using |
US20090136982A1 (en) * | 2005-01-18 | 2009-05-28 | Biocept, Inc. | Cell separation using microchannel having patterned posts |
US20110065181A1 (en) * | 2008-04-23 | 2011-03-17 | Parsortix, Inc. | Methods and Apparatus for Segregation of Particles |
-
2012
- 2012-04-13 CA CA2833026A patent/CA2833026A1/en not_active Abandoned
- 2012-04-13 AU AU2012243396A patent/AU2012243396A1/en not_active Abandoned
- 2012-04-13 US US14/112,021 patent/US9880084B2/en not_active Expired - Fee Related
- 2012-04-13 EP EP12771679.3A patent/EP2697357A4/en not_active Withdrawn
- 2012-04-13 WO PCT/CA2012/000362 patent/WO2012139209A1/en active Application Filing
- 2012-04-13 JP JP2014504129A patent/JP5990256B2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060051265A1 (en) | 2004-09-08 | 2006-03-09 | Health Research, Inc. | Apparatus and method for sorting microstructures in a fluid medium |
US20090136982A1 (en) * | 2005-01-18 | 2009-05-28 | Biocept, Inc. | Cell separation using microchannel having patterned posts |
WO2007021409A1 (en) * | 2005-08-11 | 2007-02-22 | University Of Washington | Separation and concentration channel with determined pore shape |
US20070161051A1 (en) * | 2006-01-12 | 2007-07-12 | Biocept, Inc. | Device for cell separation and analysis and method of using |
US20110065181A1 (en) * | 2008-04-23 | 2011-03-17 | Parsortix, Inc. | Methods and Apparatus for Segregation of Particles |
Non-Patent Citations (17)
Title |
---|
ASTUMIAN, R.D.: "Thermodynamics and kinetics of a Brownian motor", SCIENCE, vol. 276, no. 5314, 1997, pages 917 - 922 |
BADER, J.S. ET AL.: "DNA transport by a micromachined Brownian ratchet device", PNAS, vol. 96, no. 23, 1999, pages 13165 - 13169 |
DAVIS, J.A. ET AL.: "Deterministic hydrodynamics: Taking blood apart.", PROC. NATL. ACAD. SCI. U.S.A., vol. 103, no. 40, 2006, pages 14779 - 14784, XP055103226, DOI: doi:10.1073/pnas.0605967103 |
FAUCHEUX, L.P. ET AL.: "Optical Thermal Ratchet", PHYSICAL REVIEW LETTERS, vol. 74, no. 9, 1995, pages 1504 - 1507 |
GALAJDA, P. ET AL.: "Funnel ratchets in biology at low Reynolds number: choanotaxis", JOURNAL OF MODERN OPTICS, vol. 55, no. 19-20, 2008, pages 3413 - 3422 |
GORRE-TALINI, L.; J.P. SPATZ; P. SILBERZAN: "Dielectrophoretic ratchets", CHAOS, vol. 8, no. 3, 1998, pages 650 - 656 |
HULME, S.E. ET AL.: "Using ratchets and sorters to fractionate motile cells of Escherichia coli by length", LAB ON A CHIP, vol. 8, no. 11, 2008, pages 1888 - 1895, XP055151622, DOI: doi:10.1039/b809892a |
JASON S. KUO ET AL.: "Deformability considerations in filtration of biological cells", LAB ON A CHIP, vol. 10, no. 7, 1 January 2010 (2010-01-01), XP055129082, DOI: doi:10.1039/b922301k |
JULICHER, F.; A. AJDARI; J. PROST: "Modeling molecular motors", REVIEWS OF MODERN PHYSICS, vol. 69, no. 4, 1997, pages 1269 - 1281 |
LOUTHERBACK, K. ET AL.: "Deterministic Microfluidic Ratchet", PHYSICAL REVIEW LETTERS, vol. 102, no. 4, 2009, pages 045301, XP008141369, DOI: doi:10.1103/PhysRevLett.102.045301 |
MAHMUD, G. ET AL.: "Directing cell motions on micropatterned ratchets", NATURE PHYSICS, vol. 5, no. 8, 2009, pages 606 - 612, XP055034675, DOI: doi:10.1038/nphys1306 |
MATTHIAS, S.; F. MULLER: "Asymmetric pores in a silicon membrane acting as massively parallel brownian ratchets", NATURE, vol. 424, no. 6944, 2003, pages 53 - 57 |
MCFAUL, S. ET AL.: "Cell Separation Based on Size and Deformability Using Microfluidic Funnel Ratchets", LAB CHIP, vol. 12, no. 13, 6 June 2012 (2012-06-06), pages 2369 - 2376, XP055133270 * |
ROUSSELET, J. ET AL.: "Directional Motion of Brownian Particles Induced by a Periodic Asymmetric Potential", NATURE, vol. 370, no. 6489, 1994, pages 446 - 448, XP002374244, DOI: doi:10.1038/370446a0 |
S. ELIZABETH HULME ET AL.: "Using ratchets and sorters to fractionate motile cells of Escherichia coli by length", LAB ON A CHIP, vol. 8, no. 11, 1 January 2008 (2008-01-01), XP055151622, DOI: doi:10.1039/b809892a |
See also references of EP2697357A4 |
T. FEHM: "Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells", CYTOTHERAPY, vol. 7, no. 2, 1 May 2005 (2005-05-01), XP055151629, DOI: doi:10.1080/14653240510027082 |
Cited By (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12038438B2 (en) | 2008-07-18 | 2024-07-16 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
US9770467B2 (en) | 2012-06-08 | 2017-09-26 | Aduro Biotech, Inc. | Compositions and methods for cancer immunotherapy |
US10414789B2 (en) | 2012-12-13 | 2019-09-17 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
US9695212B2 (en) | 2012-12-13 | 2017-07-04 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
EP3029465A1 (en) * | 2013-03-15 | 2016-06-08 | ANGLE North America, Inc. | Methods for segregating particles using an apparatus with a size-discriminating separation element having an elongate leading edge |
US9939425B2 (en) | 2013-03-15 | 2018-04-10 | Angle North America, Inc. | Methods for segregating particles using an apparatus with a size-discriminating separation element having an elongate leading edge |
US10279349B2 (en) | 2013-03-15 | 2019-05-07 | Angle North America, Inc. | Methods for segregating particles using an apparatus with a size-discriminating separation element having an elongate leading edge |
US9861983B2 (en) | 2013-03-15 | 2018-01-09 | Angle North America, Inc. | Methods for segregating particles using an apparatus with a size-discriminating separation element having an elongate leading edge |
US9631179B2 (en) | 2013-03-15 | 2017-04-25 | Angle North America, Inc. | Methods for segregating particles using an apparatus with a size-discriminating separation element having an elongate leading edge |
US9851344B2 (en) | 2013-03-15 | 2017-12-26 | Angle North America, Inc. | Methods for segregating particles using an apparatus with a size-discriminating separation element having an elongate leading edge |
WO2014150928A1 (en) * | 2013-03-15 | 2014-09-25 | The Regents Of The University Of California | Devices for sorting cells in a sample and methods for use thereof |
US10583437B2 (en) | 2013-03-15 | 2020-03-10 | Angle North America, Inc. | Methods for segregating particles using an apparatus with a size-discriminating separation element having an elongate leading edge |
EP2790020A3 (en) * | 2013-03-15 | 2014-12-24 | Parsortix, Inc. | Methods for segregating particles using an apparatus with a size-discriminating separation element having an elongate leading edge |
US9840533B2 (en) | 2013-04-29 | 2017-12-12 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
US10385091B2 (en) | 2013-04-29 | 2019-08-20 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
US10131686B2 (en) | 2013-04-29 | 2018-11-20 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
US11014956B2 (en) | 2013-04-29 | 2021-05-25 | Memorial Sloan Kettering Cancer Center; The Rockefeller | Compositions and methods for altering second messenger signaling |
US11873319B2 (en) | 2013-05-03 | 2024-01-16 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type I interferon |
US9724408B2 (en) | 2013-05-18 | 2017-08-08 | Aduro Biotech, Inc. | Compositions and methods for activating stimulator of interferon gene-dependent signalling |
US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
US10653774B2 (en) | 2013-05-18 | 2020-05-19 | Aduro Biotech, Inc. | Compositions and methods for activating “stimulator of interferon gene”-dependent signalling |
US10189873B2 (en) | 2013-05-18 | 2019-01-29 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”-dependent signalling |
US20170131187A1 (en) * | 2013-06-21 | 2017-05-11 | The Regents Of The University Of California | Microfluidic tumor tissue dissociation device and method |
US11427798B2 (en) | 2013-06-21 | 2022-08-30 | The Regents Of The University Of California | Microfluidic tissue dissociation device and method |
US9580678B2 (en) | 2013-06-21 | 2017-02-28 | The Regents Of The University Of California | Microfluidic tumor tissue dissociation device |
US10683480B2 (en) | 2013-06-21 | 2020-06-16 | The Regents Of The University Of California | Microfluidic tumor tissue dissociation device and method |
US10176292B2 (en) | 2013-07-31 | 2019-01-08 | Memorial Sloan-Kettering Cancer Center | STING crystals and modulators |
EP3105570A4 (en) * | 2014-02-10 | 2017-10-11 | Technion Research & Development Foundation Ltd. | Method and apparatus for cell isolation, growth, replication, manipulation, and analysis |
US10370630B2 (en) | 2014-02-10 | 2019-08-06 | Technion Research & Development Foundation Limited | Method and apparatus for cell isolation, growth, replication, manipulation, and analysis |
CN106164658A (en) * | 2014-02-10 | 2016-11-23 | 泰克年研究发展基金会公司 | For cell separation, the method and apparatus that grows, replicate, operate and analyze |
US10183475B2 (en) | 2014-03-24 | 2019-01-22 | Fenwal, Inc. | Flexible biological fluid filters |
US10159778B2 (en) | 2014-03-24 | 2018-12-25 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US10343093B2 (en) | 2014-03-24 | 2019-07-09 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US10376627B2 (en) | 2014-03-24 | 2019-08-13 | Fenwal, Inc. | Flexible biological fluid filters |
US9968738B2 (en) | 2014-03-24 | 2018-05-15 | Fenwal, Inc. | Biological fluid filters with molded frame and methods for making such filters |
US9782707B2 (en) | 2014-03-24 | 2017-10-10 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US9796166B2 (en) | 2014-03-24 | 2017-10-24 | Fenwal, Inc. | Flexible biological fluid filters |
JP2016097121A (en) * | 2014-11-21 | 2016-05-30 | ラトックシステムエンジニアリング株式会社 | Method and program for evaluating network |
CN107690419A (en) * | 2015-09-07 | 2018-02-13 | 株式会社Lg化学 | Sheet peeling device |
WO2017043862A1 (en) * | 2015-09-07 | 2017-03-16 | 주식회사 엘지화학 | Apparatus for delaminating sheet material |
US10722540B1 (en) | 2016-02-01 | 2020-07-28 | The Regents Of The University Of California | Microfluidic device and method for shear stress-induced transformation of cells |
US10807056B2 (en) | 2016-05-11 | 2020-10-20 | Lg Chem, Ltd. | High pressure homogenizer and method for manufacturing graphene using the same |
CN109071230A (en) * | 2016-05-11 | 2018-12-21 | 株式会社Lg化学 | High-pressure homogenizer and the method for manufacturing graphene using it |
WO2017196037A1 (en) * | 2016-05-11 | 2017-11-16 | 주식회사 엘지화학 | High pressure homogenizer and method for manufacturing graphene using same |
CN109071230B (en) * | 2016-05-11 | 2022-02-01 | 株式会社Lg化学 | High pressure homogenizer and method for manufacturing graphene using the same |
KR20170127208A (en) * | 2016-05-11 | 2017-11-21 | 주식회사 엘지화학 | High pressure homogenizer and manufacturing method for Graphene using the same |
KR102079141B1 (en) | 2016-05-11 | 2020-02-19 | 주식회사 엘지화학 | High pressure homogenizer and manufacturing method for Graphene using the same |
US11579073B2 (en) | 2017-02-07 | 2023-02-14 | Nodexus Inc. | Microfluidic system with combined electrical and optical detection for high accuracy particle sorting and methods thereof |
US11674884B2 (en) | 2017-02-07 | 2023-06-13 | Nodexus Inc. | Microfluidic system with combined electrical and optical detection for high accuracy particle sorting and methods thereof |
US11686665B2 (en) | 2017-02-07 | 2023-06-27 | Nodexus Inc. | Microfluidic system with combined electrical and optical detection for high accuracy particle sorting and methods thereof |
US11733152B2 (en) | 2017-02-07 | 2023-08-22 | Nodexus Inc. | Microfluidic system with combined electrical and optical detection for high accuracy particle sorting and methods thereof |
US10926257B2 (en) | 2017-08-28 | 2021-02-23 | The Regents Of The University Of California | Microfluidic device for the digestion of tissues into cellular suspensions |
US12036550B2 (en) | 2017-08-28 | 2024-07-16 | The Regents Of The University Of California | Microfluidic device for the digestion of tissues into cellular suspensions |
US11524293B2 (en) | 2018-01-17 | 2022-12-13 | Sartorius Stedim North America Inc. | Cell separation device, method and system |
Also Published As
Publication number | Publication date |
---|---|
CA2833026A1 (en) | 2012-10-18 |
EP2697357A1 (en) | 2014-02-19 |
EP2697357A4 (en) | 2015-04-22 |
JP2014510539A (en) | 2014-05-01 |
AU2012243396A1 (en) | 2013-10-31 |
US20150300939A1 (en) | 2015-10-22 |
US9880084B2 (en) | 2018-01-30 |
JP5990256B2 (en) | 2016-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9880084B2 (en) | Apparatus for separation of particles | |
US20190072465A1 (en) | Capturing particles | |
US20140034556A1 (en) | Apparatus and method for particle separation | |
ES2968853T3 (en) | Microfluidic isolation of tumor cells or other rare cells from whole blood or other fluids | |
JP6338766B2 (en) | Microparticle separation and cleaning method using parallel laminar flow of non-Newtonian fluid and Newtonian fluid | |
US20140008210A1 (en) | Methods and compositions for separating or enriching cells | |
KR20150061643A (en) | Micro-fluidic device and uses thereof | |
Gourikutty et al. | An integrated on-chip platform for negative enrichment of tumour cells | |
EP2908140A1 (en) | Microchannel chip for microparticle separation, microparticle separation method and system for microparticle separation using chip | |
Yang et al. | A novel rare cell sorting microfluidic chip based on magnetic nanoparticle labels | |
EP2659984B1 (en) | Apparatus for self-extracting cells using magnetic force and method for self-extracting cells using the same | |
Mohamed | Use of microfluidic technology for cell separation | |
Dias | Microfabrication of a Microfluidic Device for Cell Sorting: Isolation of Both Circulating Tumour Cell (CTC) and Giant Cancer Associated Macrophage-Like Cells (CAMLs) | |
Chen | Flow and Interaction Patterns between Tumor Cells and Microfabricated Structures | |
Tran | Microfluidic studies on flow manipulation to assist metastasis research | |
McFaul | Physical cell separation using microfluidic funnel ratchets | |
Ahmad et al. | Microfluidic Particle Separation and Biomedical Applications | |
Yılmaz | Development of a cell sorting platform based on magnetic levitation principle | |
Fiorentini | Impact of cell deformability on inertial focusing in spiral and straight microfluidic channels | |
Esmaeilsabzali | Development of a microfluidic platform for size-based enrichment and immunomagnetic isolation of circulating tumour cells | |
Öksüz | Cell separation in microfluidic devices | |
Feng | Particle Manipulation and Separation in Inertial and Viscoelastic Flow | |
Tran | Deterministic Lateral Displacement for Cell Sorting | |
Ohiri | Acoustofluidic Innovations for Cellular Processing On-Chip | |
Yilmaz | Design and fabrication of low cost passive microfluidic systems for particle separation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12771679 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014504129 Country of ref document: JP Kind code of ref document: A Ref document number: 2833026 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2012771679 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012771679 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2012243396 Country of ref document: AU Date of ref document: 20120413 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14112021 Country of ref document: US |